<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04475510</url>
  </required_header>
  <id_info>
    <org_study_id>HALTI</org_study_id>
    <nct_id>NCT04475510</nct_id>
  </id_info>
  <brief_title>Discontinuation of Antithrombotic Treatment Following Patent Foramen Ovale Closure in Young Patients With Cryptogenic Stroke</brief_title>
  <acronym>HALTI</acronym>
  <official_title>Discontinuation of Antithrombotic Treatment Following Patent Foramen Ovale Closure in Young Patients With Cryptogenic Stroke. The HALTI Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Josep Rodes-Cabau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the safety of antithrombotic treatment discontinuation 12 months following
      successful transcatheter PFO closure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Young patients with a cryptogenic ischemic event undergoing transcatheter PFO closure exhibit
      a low but clinically relevant risk of bleeding (overall and major bleeding) at long-term
      follow-up, eventually exceeding the risk of ischemic events.

      Importantly, the vast majority of major bleeding events seem to occur in patients receiving
      antiplatelet therapy. Preliminary data suggest that antiplatelet therapy discontinuation is
      not associated with any increase in ischemic events, and could potentially translate into a
      lower rate of major bleeding events at longer term follow-up. We therefore hypothesize that
      in young patients without any other comorbidities increasing the risk of stroke, shorter-term
      (≤1 year instead of lifelong) antiplatelet treatment could be a safe option following PFO
      closure.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2032</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>At 12 months post-PFO closure, patients will discontinue the antiplatelet treatment. All patients will undergo a clinical evaluation and cerebral MRI at 12 months (before antiplatelet treatment cessation) and at 24 months post-PFO closure.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>New stroke events</measure>
    <time_frame>12 months</time_frame>
    <description>1)Acute episode of a focal or global neurological deficit with at least one of the following: change in level of consciousness, hemiplegia, hemiparesis, numbness or sensory loss affecting one side of the body, dysphasia or aphasia, hemianopia, amaurosis fugax or other new neurological symptom(s) consistent with stroke.(2)Duration of a focal or global neurological deficit ≥ 24 hours OR &lt; 24 hours if available neuroimaging documents a new hemorrhage or infarct; OR the neurological deficit results in death.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>New ischemic lesions</measure>
    <time_frame>24-month follow-up</time_frame>
    <description>Evaluated by MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of new cerebral ischemic lesions</measure>
    <time_frame>24-month follow-up</time_frame>
    <description>Evaluated by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of new cerebral ischemic lesions</measure>
    <time_frame>24-month follow-up</time_frame>
    <description>Evaluated by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemic events</measure>
    <time_frame>24-month follow-up</time_frame>
    <description>Stroke, TIA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemic events</measure>
    <time_frame>3-year follow-up</time_frame>
    <description>Stroke, TIA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemic events</measure>
    <time_frame>4-year follow-up</time_frame>
    <description>Stroke, TIA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemic events</measure>
    <time_frame>5-year follow-up</time_frame>
    <description>Stroke, TIA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemic events</measure>
    <time_frame>6-year follow-up</time_frame>
    <description>Stroke, TIA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemic events</measure>
    <time_frame>7-year follow-up</time_frame>
    <description>Stroke, TIA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemic events</measure>
    <time_frame>8-year follow-up</time_frame>
    <description>Stroke, TIA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemic events</measure>
    <time_frame>9-year follow-up</time_frame>
    <description>Stroke, TIA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemic events</measure>
    <time_frame>10-year follow-up</time_frame>
    <description>Stroke, TIA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>24-month follow-up</time_frame>
    <description>Life-threatening, major or minor bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>3-year follow-up</time_frame>
    <description>Life-threatening, major or minor bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>4-year follow-up</time_frame>
    <description>Life-threatening, major or minor bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>5-year follow-up</time_frame>
    <description>Life-threatening, major or minor bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>6-year follow-up</time_frame>
    <description>Life-threatening, major or minor bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>7-year follow-up</time_frame>
    <description>Life-threatening, major or minor bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>8-year follow-up</time_frame>
    <description>Life-threatening, major or minor bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>9-year follow-up</time_frame>
    <description>Life-threatening, major or minor bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>10-year follow-up</time_frame>
    <description>Life-threatening, major or minor bleeding</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Patent Foramen Ovale</condition>
  <condition>Ischemic Stroke</condition>
  <condition>Bleeding Ulcer</condition>
  <arm_group>
    <arm_group_label>Antiplatelet treatment discontinuation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At 12 months post-PFO closure, patients will discontinue the antiplatelet treatment. All patients will undergo a clinical evaluation and cerebral MRI at 12 months (before antiplatelet treatment cessation) and at 24 months post-PFO closure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Antiplatelet treatment discontinuation</intervention_name>
    <description>All patients will undergo a clinical evaluation and cerebral MRI at 12 months (before antiplatelet treatment cessation) and at 24 months post-PFO closure.</description>
    <arm_group_label>Antiplatelet treatment discontinuation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Successful transcatheter PFO closure with any approved device

          -  Patients ≤60 years diagnosed with a cryptogenic stroke/TIA who have undergone
             successful transcatheter PFO closure

        Exclusion Criteria:

        -&gt;60 year-old

          -  RoPE score &lt;6

          -  Residual shunt ≥moderate following PFO closure

          -  Atrial fibrillation following PFO closure

          -  Presence of ≥2 cardiovascular risk factors (smoking, hypertension, dyslipidemia)

          -  Diabetes mellitus

          -  Thrombophilia (factor V Leiden, factor II mutation, anticardiolipin antibodies, lupus
             anticoagulant, anti-b2 glycoprotein-I antibodies, protein C deficiency, protein S
             deficiency)

          -  Recurrent cerebrovascular event (stroke, TIA) within the year following PFO closure

          -  Failure to provide signed informed consent

          -  Absolute contraindications for an MRI study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Josep Rodes-Cabau, MD</last_name>
    <phone>4186568711</phone>
    <email>josep.rodes@criucpq.ulaval.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Melanie Cote, MSc</last_name>
    <phone>14186537270</phone>
    <email>melanie.cote@criucpq.ulaval.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IUCPQ</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Josep Rodes-Cabau, MD</last_name>
      <phone>4186568711</phone>
      <email>josep.rodes@criucpq.ulaval.ca</email>
    </contact>
    <contact_backup>
      <last_name>Melanie Cote, MSc</last_name>
      <phone>4186568711</phone>
      <phone_ext>Rodes-Cabau</phone_ext>
      <email>josep.rodes@criucpq.ulaval.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Josep Rodes-Cabau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 14, 2020</study_first_submitted>
  <study_first_submitted_qc>July 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2020</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</investigator_affiliation>
    <investigator_full_name>Josep Rodes-Cabau</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Transcatheter Patent Foramen Ovale (PFO) closure</keyword>
  <keyword>Ischemic Stroke</keyword>
  <keyword>Bleeding</keyword>
  <keyword>Young patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Foramen Ovale, Patent</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

